You are here

Home » Content

TTF-1 (Clone SPT24) and CD 99 Positivity in Glioblastoma: A Diagnostic Dilemma

TTF-1 (Clone SPT24) and CD 99 Positivity in Glioblastoma: A Diagnostic Dilemma

Journal Name:

  • Akdeniz Tıp Dergisi

Publication Year:

  • 2015
DOI: 
10.17954/amj.2015.08

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
We describe an unusual variant of glioblastoma with small cell morphology and discuss its remarkable immunoprofile. Glioblastoma multiforme comprises a morphologically highly heterogeneous neoplasm. However, this heterogeneous immunoprofile of glioblastoma can lead to confusion in the differential diagnosis. A 64-year-old male presented to our hospital. A temporal mass was detected on magnetic resonance examination and surgery was performed. The tumor was composed of a monomorphic collection of densely packed and mitotically active small astrocytes. Proliferated microvessels and palisading necrosis were seen in tumoral areas. Immunohistochemical analysis revealed that the tumor cells expressed GFAP, CD56, NSE, CD99 and TTF-1 (clone SPT24) but there was no expression of clone 8G7G3/1 of TTF- 1. TTF-1 expression in glioblastomas cannot rule out primary tumor of the central nervous system even when there is diffuse and strong staining. The clinical and histopathological parameters should be evaluated together for the diagnosis.
Bookmark/Search this post with
Abstract (Original Language): 
Nadir bir varyant olan küçük hücre morfolojisine sahip glioblastom olgusunu dikkat çekici immünoprofili ile tanımladık. Glioblastoma multiforme morfolojik olarak oldukça heterojen bir gruptur. Bununla birlikte, glioblastom heterojen profili ayırıcı tanıda karışıklığa yol açabilir. 64 yaşında erkek hasta hastanemize başvurdu, magnetik rezonans incelemede temporal kitle tespit edildi ve cerrahi uygulandı. Tümör monomorfik sıkışık gruplar yapan, mitotik olarak aktif küçük astrositlerden oluşmaktaydı. Tümöral alanlarda prolifere küçük damarlar, palizatlanan nekroz izlendi. İmmünohistokimyasal analiz yapıldı, tümör hücreleri GFAP, CD56, NSE, CD99 VE TTF-1 (klon SPT24) ekprese ederken TTF-1, klon 8G7G3/1 ile ekspresyon izlenmedi. Glioblastomlarda TTF-1 ekspresyonu diffüz ve güçlü olsa bile santral sinir sisteminin primer tümörünü dışlayamaz. Tanı için klinik ve histopatolojik parametrelerin birlikte değerlendirilmesi gerekmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-ttf-1-clone-spt24-and-cd-99-positivity-glioblastoma-diagnostic-dilemma.pdf
  • 1
64
67
  • Turkish

REFERENCES

References: 

1. Central Brain Tumor Registry of the United States.
Statistical Report. Primary Brain Tumors in the United
States, 1998-2002. Hinsdale, Ill: Central Brain Tumor
Registry of the United States; 2006.
2. Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med
2007;131:397-406.
3. Bari KU, Danish R, Azher Q , Karim AS. Glioblastoma
multiforme in a patient with a small cell lung cancer: Case
report. Clin Neurol Neurosurg 2011;113:78-9.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger
PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO
classification of tumours of the central nervous system. Acta
Neuropathol 2007;114:97-109.
5. Kristensen MH, Nielsen S, Vyberg M. Thyroid transcription
factor-1 in primary CNS tumors. Appl Immunohistochem
Mol Morphol 2011;19:437-43.
6 Matoso A, Resnick MB, Wang LJ. Comparison of 2
monoclonal TTF-1 antibodies. Appl Immunohistochem
Mol Morphol 2011;19:384.
7. Dettmer M, Kim TE, Jung CK, Jung ES, Lee KY, Kang
CS. Thyroid transcription factor-1 expression in colorectal
adenocarcinomas. Pathol Res Pract 2011;207:686-90.
8. Bisceglia M, Galliani C, Rosai J. TTF-1 expression in breast
carcinoma-the chosen clone matters. Am J Surg Pathol
2011;35:1087-8.
9. Z amecnik J, Chanova M, Kodet R. Expression of thyroid
transcription factor 1 in primary brain tumours. J Clin
Pathol 2004;57:1111-3.
10. Galloway M, Sim R. TTF-1 staining in glioblastoma
multiforme. Virchows Arch 2007;451:109-11.11. Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas
NK. Thyroid transcription factor 1 expression in sellar
tumors: A histogenetic marker? J Neuropathol Exp Neurol
2009;68:482-8.
12. Robens J, Goldstein L, Gown AM, Schnitt SJ. Thyroid
transcription factor-1 expression in breast carcinomas. Am
J Surg Pathol 2010;34:1881-5.
13. Compérat E, Zhang F, Perrotin C, Molina T, Magdeleinat
P, Marmey B, Régnard JF, Audouin J, Camilleri-Broët S.
Variable sensitivity and specificity of TTF-1 antibodies in
lung metastatic adenocarcinoma of colorectal origin. Mod
Pathol 2005;18:1371-6.
14. Penman D, Downie I, Roberts F. Positive immunostaining
for thyroid transcription factor-1 in primary and metastatic
colonic adenocarcinoma: A note of caution. J Clin Pathol
2006;59:663-4.
15. Scotlandi K. Targeted therapies in Ewing’s sarcoma. Adv
Exp Med Biol 2006;587:13-22.
16. Visée S, Soltner C, Rialland X, Machet MC, Loussouarn D,
Milinkevitch S, Pasco-Papon A, Mercier P, Rousselet MC.
Supratentorial primitive neuroectodermal tumours of the
brain: Multidirectional differentiation does not influence
prognosis. A clinicopathological report of 18 patients.
Histopathology 2005;46:403-12.
17. Choi YL, Chi JG, Suh YL. CD99 immunoreactivity in
ependymoma. Appl Immunohistochem Mol Morphol
2001;9:125-9.
18. Ishizawa K, Komori T, Shimada S, Hirose T. Olig2 and
CD99 are useful negative markers for the diagnosis of brain
tumors. Clin Neuropathol 2008;27:118-28.

Thank you for copying data from http://www.arastirmax.com